Zeleris (fezolinetant vet. analog)

About Vetoquinol

Vetoquinol's mission is to advance animal health through applied veterinary science, serving as a trusted, independent partner to veterinarians, farmers, and pet owners worldwide. The company has achieved steady growth, with €545 million in 2023 sales, by focusing on formulation innovation, lifecycle management, and geographic expansion. Its strategy is built on three pillars: maintaining independence from Big Pharma, controlling a vertically integrated value chain from R&D to manufacturing, and cultivating deep, direct relationships with the veterinary community.

Therapeutic Areas

Other Canine Atopic Dermatitis Drugs